Article Details
Retrieved on: 2025-09-09 19:28:17
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
and Kyowa Kirin's rocatinlimab, an anti-OX40 monoclonal antibody targeting T-cell dysregulation. The Phase 3 ASCEND trial, which evaluated ...
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here